8-K: Envoy Medical Secures $10 Million Funding to Advance Cochlear Implant Trial

Envoy Medical obtains $10 million in financing from Glen Taylor to support the Acclaim cochlear implant pivotal clinical trial and other operations.

Summary

• Envoy Medical has secured a $10 million loan from GAT Funding, LLC, an entity controlled by Glen Taylor, a board member and controlling stockholder.
• The loan will support the Acclaim cochlear implant pivotal clinical trial and other operations.
• The loan has a five-year term, maturing on March 6, 2030, with an 8% interest rate.
• Interest accrues for the first two years and is compounded annually.
• The company can draw funds in $2.5 million tranches.
• An initial $5 million was drawn at closing on March 11, 2025.
• Envoy Medical issued warrants to GAT to purchase 750,000 shares of Class A Common Stock at $1.35 per share as part of the initial funding.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the secured funding, which will support the company's clinical trial and operations. However, the debt and potential dilution from warrants temper the enthusiasm.

Positives

• The $10 million funding provides Envoy Medical with additional capital during a transformative year.
• The funds will support the pivotal clinical trial of the Acclaim Cochlear Implant.
• The loan is unsecured and does not have a conversion feature.
• Interest is deferred for the first two years, providing some financial flexibility.
• The company has the option to prepay the accrued interest and principal without penalty with 10 days notice.

Negatives

• The company is taking on debt, which will increase its financial obligations.
• The warrants issued to GAT could dilute existing shareholders' equity.
• The interest rate of 8% could be considered relatively high.

Risks

• The Acclaim Cochlear Implant is an investigational device and is subject to regulatory approval.
• Clinical trials may not be successful.
• The company faces competition in the medical device industry.
• Changes in market conditions or economic performance could impact the company's ability to repay the loan.
• The company's success depends on retaining key employees and directors.

Future Outlook

The company expects a transformative year with important milestones related to the Acclaim cochlear implant pivotal clinical trial.

Management Comments

• Envoy Medical CEO Brent Lucas stated they are very happy with the enrollment progress in the first stage of the pivotal clinical trial.
• Investigational sites are reporting a tremendous amount of interest in the fully implanted cochlear implant.
• Management believes that interest will only grow as awareness is increased and further progress is made.
• Management is bullish on the reported desire of many cochlear implant candidates to have a device that is designed to be completely internal.

Industry Context

The announcement highlights the ongoing innovation and investment in the hearing health industry, particularly in fully implanted hearing devices. Envoy Medical's Acclaim CI aims to compete with existing cochlear implant solutions by offering a fully implanted design.

Comparison to Industry Standards

• Envoy Medical's Esteem FI-AMEI is the only FDA-approved, fully implanted active middle ear implant, setting it apart from competitors that offer hearing aids or partially implanted devices.
• Companies like Cochlear Limited and Med-El offer cochlear implant systems, but Envoy Medical aims to differentiate itself with its fully implanted technology and sensor design that leverages the natural anatomy of the ear.
• The $10 million funding will allow Envoy Medical to continue its clinical trials and compete with larger, more established players in the hearing health market.

Related Party Transactions

• The loan from GAT Funding, LLC, an entity controlled by Glen Taylor, a member of the Company's board of directors and the controlling stockholder, is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of warrants.
• Employees benefit from the continued funding of operations and clinical trials.
• Potential customers (individuals with hearing loss) may benefit from the development of the Acclaim Cochlear Implant.
• The company's suppliers and creditors are likely to be positively impacted by the increased financial stability.

Next Steps

• Continue enrollment in the pivotal clinical trial for the Acclaim Cochlear Implant.
• Utilize the funding to support operations and advance the development of the Acclaim CI.
• Monitor the progress of the clinical trial and prepare for potential regulatory submissions.

Key Dates